April 29, 2018 | Israel’s Kanabo Research, a R&D company that develops clinical solutions for the extraction and vaporization of medical cannabis, announced that it was partnering with Constance Therapeutics, a US-based medical cannabis extraction company, to set up a cannabis cultivation farm in Europe. According to the deal, Kanabo Research and Constance Therapeutics will operate the farm “as well as manufacturing capabilities of cannabis active compounds – THC and CBD – to be used in an array of medical treatments and chronic ailments such as insomnia, PTSD and chronic pain.” Constance Therapeutics will also market Kanabo Research’s solutions in the US. Kanabo Research co-founder and CEO Avihu Tamir said the company was happy to partner with Constance Therapeutics, while “operating to locate global opportunities in light of the fact that many countries are asking to join the medical cannabis revolution.” Tamir said the partnership “will allow us to accelerate our manufacturing pace – especially important now because of the delays in medical cannabis export approvals in Israel – and will provide us with an excellent base for additional operations in other markets, primarily European markets.” Constance Finley, founder and CEO of Constance Therapeutics said, “This is a natural fit and extends each company’s expertise into new territories and most importantly, offers emerging cannabis customers the most innovative and enjoyable option.” Kanabo Research developed the VapePod vaporizer, receiving initial approvals from Israel’s Ministry of Health to use cannabis with the proprietary vaporizer, and making Israel the first country in the world to approve the use of a medical cannabis vaporizer. Kanabo said it has also started pre-clinical trials of Kanabo’s proprietary formulations that focus on sleep disorders and in the future for patients suffering from PTSD.